Compare Albemarle Corp. (ALB) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs CVS Health Corp — how do they compare? Albemarle Corp. trades at $130.05 (market cap $15.48B), while CVS Health Corp trades at $93.65 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 7.9× Albemarle Corp.'s market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| ALB | CVS | |
|---|---|---|
Market Cap | $15.48B | $122.36B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $110.60 |
52-Week Low | $72.58 | $64.88 |
Enterprise Value | $17.96B | $184.71B |
Dividend Yield | 1.25% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.11, up 4.54% today, with a bullish technical signal and strong Q2 2026 earnings beating estimates. The stock shows improved cash flow and lithium demand strength, though valuation metrics like a P/E of 485.59 indicate high expectations. Recent news highlights earnings growth and dividend stability, with support at $127 and resistance at $134.
Outlook is cautiously optimistic with analyst consensus target of $184.50, but risks include volatile lithium prices and high valuation. Investment opportunity lies in sustained demand for energy storage, balanced by margin pressures and debt levels.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
